Table 4.
Clinical and treatment details of the 8 patients who received sequential chemoradiotherapy
| Patient | Age | Sex | PS | Site | CT | Cycles (n) | RT dose | Response | Site of relapse | 2nd Line CT | Survival (mo) |
| 1 | 52 | F | 0 | Mid | CE | 6 | 50 Gy in 20 Fr | CR | Liver | 2 Top | 25 |
| 2 | 78 | F | 0 | Low | PE | 1 | 50 Gy in 20 Fr | CR | UK | None | 25 |
| 3 | 71 | M | 0 | Low | CE/PE | 3 | 50 Gy in 20 Fr | CR | Local | 6 PE | 23 |
| 4 | 70 | M | 1 | Low1 | PE | 5 | 50 Gy in 20 Fr | PR | Local | 2 PE | 20 |
| 5 | 67 | F | 1 | Low | CE | 4 | 45 Gy in 25 Fr | PR | Local2 | 3 ECX | 65.5 |
| 6 | 70 | F | 1 | Low | CE | 4 | 50 Gy in 20 Fr | UK | UK | None | 19 |
| 7 | 73 | F | 1 | Low | PE | 4 | 4005 cGy in 15 Fr | PR | UK | None | 17 |
| 8 | 69 | M | 1 | Low1 | PE | 5 | 50 Gy in 25 Fr | PR | UK | 2 PE | 20 |
1
Mixed pathology of small cell oesophageal cancer and adenocarcinoma.
2
New primary with adenocarcinoma, patient had palliative chemotherapy. CE: Cisplatin and etoposide; CR: Complete response; CT: Chemotherapy; Fr: Fractions; M: Male; Mid: Middle; PE: Carboplatin and etoposide; Low: Lower; PS: Performance status; PR: Partial response; RT: Radiotherapy; Top: Topotecan; UK: Unknown; 2nd Line CT: Second line chemotherapy.